Compound Taxus chinensis Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials
Table 2
The summary of the current meta-analysis results.
Outcome/subgroup
Number of studies
Number of participants
The selected statistical methods
Pooled effect size
DCR
6
410
RR (fixed), 95% CI
1.15 [01.06, 1.25]
0.0006
OR (fixed), 95% CI
2.80 [1.54, 3.58]
0.0007
RD (fixed), 95% CI
0.12 [0.06, 0.19]
0.0003
ORR
6
410
RR (fixed), 95% CI
1.15 [01.06, 1.25]
<0.0001
OR (fixed), 95% CI
2.35 [1.54, 3.58]
<0.0001
RD (fixed), 95% CI
0.19 [0.10, 0.27]
<0.0001
KPS
3
194
SMD (random), 95% CI
1.50 [1.17, 1.82]
<0.00001
MD (fixed), 95% CI
8.69 [7.26, 10.13]
<0.00001
Adverse reactions
Gastrointestinal
4
274
RR (fixed), 95% CI
0.6[0.43, 0.86]
0.04
OR (fixed), 95% CI
0.47[0.28, 0.78]
0.004
RD (fixed), 95% CI
−0.17[−0.28, −0.06]
0.003
Leukopenia
3
202
RR (fixed), 95% CI
0.44[0.27, 0.71]
0.0009
OR (fixed), 95% CI
0.31[0.16, 0.60]
0.0006
RD (fixed), 95% CI
−0.22[−0.34, −0.10]
0.0003
Thrombocytopenia
2
144
RR (fixed), 95% CI
0.35[0.16, 0.78]
0.010
OR (fixed), 95% CI
0.28[0.11, 0.71]
0.01
RD (fixed), 95% CI
−0.18 [−0.30, −0.06]
0.004
Fever
2
144
RR (fixed), 95% CI
0.28 [0.11, 0.71]
0.007
OR (fixed), 95% CI
0.22 [0.08, 0.64]
0.005
RD (fixed), 95% CI
−0.18 [−0.29, -0.07]
0.002
Rash
2
144
RR (fixed), 95% CI
0.48 [0.26, 0.87]
0.02
OR (fixed), 95% CI
0.37 [0.17, 0.82]
0.01
RD (fixed), 95% CI
−0.18 [−0.32 −0.04]
0.01
Favours the experimental group with statistical significance. DCR, disease control rate; RR, relative ratio; OR, odds ratio; CI, confidence intervals; RD, risk difference; ORR, objective response rate; KPS: Karnofsky health score; SMD, standardized mean difference; MD, mean difference; QOL, quality of life; WMD, weighted mean difference.
